DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 5 Morgan Stanley - 4 — - 4 Jim Cramer - 4 Eli Lilly - 4 Jim Cramer's - 4 Jim - 4 Snowflake - 3
Top related locs:
U.S New York City China California Europe Ulta XPeng Canada
Top related orgs:
CNBC - 8 Nvidia - 6 Therapeutics - 6 Viking Therapeutics - 5 Bank of America - 3 Netflix - 3 Energy - 3 Dow Jones - 3

Search resuls for: "THERAPEUTICS"


25 mentions found


☆ Here are Thursday's biggest analyst calls: Nvidia, Tesla, Salesforce, Chevron, Dell, Snowflake, Netflix & more
  + stars: | 2024-11-21 | by ( Michael Bloom | ) www.cnbc.com   time to read: +5 min
Goldman Sachs downgrades XPeng to neutral from buy Goldman downgraded the China EV company mainly on valuation. Goldman Sachs reiterates Chevron as buy Goldman raised its price target on the stock to $170 per share from $167. Goldman Sachs initiates Merus Therapeutics as buy Goldman said the biotech company has "best-in-class" potential. Goldman Sachs reiterates Snowflake as buy The firm said it likes the company's "strong execution" following earnings on Wednesday. Goldman Sachs reiterates Salesforce as buy Goldman said it's sticking with shares of Salesforce.
Persons: Goldman Sachs, Morgan Stanley, Rosenblatt, William Blair downgrades Ulta, William Blair, XPeng, Goldman, Wells, Jake Paul, Mike Tyson, Dell, Snowflake, Tesla, TJX, Salesforce Organizations: Nvidia, UMB, Palo Alto Networks, Palo, China EV, GE, Bank of America, Netflix, Citi, Energy, Chevron, Barclays, Royal Bank of Canada, Merus Therapeutics, " Bank of America, JPMorgan, Networks, Palo Alto, TJX Companies Locations: Ulta, XPeng, Canada, Shanghai, Salesforce
☆ Stocks making the biggest moves midday: Netflix, Alphabet, Nvidia, BJ's Wholesale Club and more
  + stars: | 2024-11-21 | by ( Pia Singh | In | ) www.cnbc.com   time to read: +3 min
Nvidia — Shares of the chipmaker dipped about 1% in midday trading, after gyrating earlier in the session. Analysts polled by LSEG had called for earnings of 75 cents per share on $33.16 billion in revenue. Baidu — U.S. shares of the Chinese search engine fell about 5% after Baidu's third-quarter revenue declined by 3% compared to the year-ago period . BJ's Wholesale Club — Shares moved 9% higher after the warehouse club's third-quarter adjusted earnings beat the Street's estimates. The company said it will increase its membership fee and announced plans to repurchase $1 billion shares.
Persons: LSEG, Snowflake, Sridhar Ramaswamy, Merus, Goldman Sachs, — Stocks, Michael Novogratz, MicroStrategy, Miner Mara Holdings, BJ's, PDD, — CNBC's Sean Conlon, Yun Li, Michelle Fox Organizations: Nvidia —, Nvidia, Baidu, Department of Justice, Google, Chrome, Netflix, of America, —, Galaxy Digital, Miner, BJ's Wholesale, PDD Holdings
☆ Goldman says this pharma stock can rally nearly 70% thanks to key cancer treatment
  + stars: | 2024-11-21 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Goldman Sachs sees big gains ahead for Merus on the back of the company's cancer treatment. The firm initiated coverage of the cancer therapeutics stock with a buy rating on Wednesday, alongside a $73 per share price target. Law said the antibody has already shown promising results and can be a key growth driver for the stock moving forward. MRUS YTD mountain Merus stock. Merus stock has advanced more than 56% already in 2024.
Persons: Goldman Sachs, Richard Law, Law, peto Organizations: Merus
☆ Stocks making the biggest moves premarket: Snowflake, Nvidia, BJ's Wholesale and more
  + stars: | 2024-11-21 | by ( Sean Conlon | ) www.cnbc.com   time to read: +2 min
Snowflake posted adjusted earnings of 20 cents per share on revenue of $942 million. Analysts surveyed by LSEG were looking for 15 cents in earnings per share on revenue of $897 million. Nvidia – Shares of the chipmaker fell around 1% despite its third-quarter earnings results topping Wall Street's expectations . BJ's Wholesale Club – The stock popped nearly 8% after the warehouse club reported a third-quarter earnings beat and raised its full-year guidance. BJ's also announced a plan to repurchase $1 billion shares and said it will raise its membership fee.
Persons: Snowflake, LSEG, – Stocks, bitcoin, Coinbase, Mara Holdings, Baidu, BJ's, Goldman Sachs, —, Sarah Min, Hakyung Kim, Michelle Fox Theobald Organizations: Palo Alto Networks, Nvidia –, –, Baidu, BJ's Wholesale Locations: Palo
☆ Jefferies says buy this pharmaceutical play, sees more than 100% upside from here
  + stars: | 2024-11-19 | by ( Sean Conlon | ) www.cnbc.com   time to read: +3 min
Aclaris Therapeutics' recent drug developments could spell more gains ahead, according to Jefferies. Analyst Roger Song upgraded the stock to buy from hold and hiked his price target by $5 to $7, implying about 123% upside from Monday's close. ACRS YTD mountain ACRS, year-to-date Song specifically pointed to the strength of its BSI-045B treatment, which is an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody for atopic dermatitis (AD). If success, BSI-045B could be the 1st anti-TSLP in the crowded AD space providing differentiated [mechanism of action] [with] improved efficacy [and] safety." This comes as the company announced on Monday that it entered into an exclusive license agreement with Biosion for worldwide rights, excluding greater China, to both that drug and its other anti-TSLP drug known as BSI-502.
Persons: Roger Song, Biosion, Jefferies, Piper Sandler, Christopher Raymond, derm Organizations: Therapeutics, Jefferies, BSI Locations: China, Aclaris
☆ 'Mag 7' leads reversal — plus, we're adding a new stock to our Bullpen watchlist
  + stars: | 2024-11-19 | by ( Jeff Marks | ) www.cnbc.com   time to read: +5 min
Next, we are going outside our current holdings and adding drugmaker Bristol Myers Squibb to the Bullpen, our watchlist of stocks that could join the portfolio. New Jersey-based Bristol Myers is in the midst of a transition phase under the leadership of new CEO Chris Boerner. Companies reporting earnings before the open Wednesday include Club stock TJX Companies , along with Target , Williams-Sonoma , and ZIM Integrated . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Robert F, Kennedy Jr, Kennedy, Donald Trump, Wall, Eli Lilly, Bristol Myers, Chris Boerner, Boerner, Karuna, we'll, Stanley Black, Decker, Jim Cramer's, Jim Organizations: CNBC, ., Club, Nvidia, Dow Jones, of Health, Human Services, Senate, Bristol Myers Squibb, Bristol, pharma, Karuna Therapeutics, FDA, JPMorgan, Keysight Technologies, TJX Companies, Target, Williams, ZIM, Jim Cramer's Charitable Locations: New Jersey, U.S, Sonoma
☆ 5 new weight-loss drugs to watch in the fight for the next Ozempic
  + stars: | 2024-11-16 | by ( ) www.businessinsider.com   time to read: +8 min
"Forthcoming medications take the blockbuster GLP-1 medications and up the ante." Like semaglutide (the active ingredient in Ozempic and Wegovy), it works on GLP-1, a hormone that regulates blood sugar and appetite. CagriSema adds it to the already-popular drug semaglutide, which itself helps manage hunger and blood sugar levels. "Longer-acting versions of GLP-1 medications offer the potential for greater convenience and potentially improved adherence and sustained use over time," McGowan said. Timeline: Data from Phase II trials is expected later this year, and planning is underway for Phase III trials.
Persons: Eli Lilly, Dr, Christopher McGowan, Eli Lilly's, Ozempic, retatrutide, VK2735, we've, they're, McGowan Organizations: Pharma, Novo Nordisk, Viking Therapeutics, Triple, Therapeutics, FDA, orforglipron, Nordisk, Reuters Locations: GLP, Mounjaro, California
☆ Cathie Wood says her 'volatile' ARK Innovation fund shouldn't be a 'huge slice of any portfolio'
  + stars: | 2024-11-15 | by ( Samantha Subin | ) www.cnbc.com   time to read: +1 min
Cathie Wood, CEO of Ark Invest, speaks during an interview on CNBC on the floor of the New York Stock Exchange (NYSE) in New York City, February 27, 2023. Cathie Wood is defending her underperforming ARK Innovation exchange traded fund following a rocky stretch. Since then, the fund has underperformed, fueling skepticism over the Ark Invest CEO's investment strategies. She called out the multiomics life sciences and health care sectors as the biggest drag on the fund. "We think we're a very good complement to the broad-based benchmarks out there, because we don't look anything like them," she said of her fund.
Persons: Cathie Wood, CNBC's, Wood Organizations: Ark Invest, CNBC, New York Stock Exchange, Innovation, Ark, Intellia Locations: New York City
☆ Bank of America says Trump's win will unlock small-cap M&A and these stocks may be takeover candidates
  + stars: | 2024-11-15 | by ( Sean Conlon | ) www.cnbc.com   time to read: +3 min
President-elect Donald Trump's White House victory could boost merger and acquisition activity, and Bank of America thinks a group of small-cap stocks may benefit as target candidates. Financial services company Bread Financial Holdings turned up, having a float of 98% of shares outstanding and three-year sales growth of 28%. The biopharmaceutical company has a float of 99% and three-year sales growth of 105%. Commercial Metals Company also showd up on BofA's screen as a potential target. Commercial Metal's three-year sales growth was 18%.
Persons: Donald Trump's, Russell, that's, Lina Khan, Jill Carey, Irving, steelmaker Organizations: Bank of America, Dow Jones Industrial, Republican, House, Senate, Trump, FTC, GOP, Financial, Bread Financial Holdings, Halozyme Therapeutics, Commercial Metals Company Locations: Columbus , Ohio, Diego, Texas
☆ 23andMe reports sales decline day after announcing plans to cut 40% of workforce
  + stars: | 2024-11-12 | by ( Ashley Capoot | In | ) www.cnbc.com   time to read: +2 min
23andMe on Tuesday reported declining revenue in its most recent quarter, a day after the company said it will cut 40% of its workforce and shutter its therapeutics business as part of a business restructuring plan. The genetics company reported $44.1 million in revenue for the fiscal second quarter, down from $50 million in the same period last year. 23andMe's net loss narrowed to $59.1 million, or a $2.32 per share, from $75.27 million, or $3.17 per share, a year ago. It's evaluating strategic options like asset sales and licensing agreements to "maximize the value" of the therapeutic programs, the release said. Wojcicki has repeatedly stated her intention to take 23andMe private, though she didn't address the plans on Tuesday.
Persons: Anne Wojcicki, They've, 23andMe, Wojcicki Organizations: Nasdaq, NASDAQ, SEC
☆ How Pilates can help with knee pain
  + stars: | 2024-11-10 | by ( Melanie Radzicki Mcmanus | ) edition.cnn.com   time to read: +7 min
About 25% of adults experience knee pain, according to a 2018 study published in the journal American Family Physician. The report also found the prevalence of knee pain has increased 65% over the past 20 years. Osteoarthritis is often the cause of knee pain, especially for women and older adults, according to the Arthritis Foundation. Experts agree these five exercises should help alleviate knee pain, although they are not cure-alls. “While it’s impossible to say how much they’ll help any given person, incorporating these exercises could help relieve about 20% to 30% of your knee pain,” Kreitenberg said.
Persons: ”, Adam Kreitenberg, “, Shari Berkowitz, ” Berkowitz, it’s, Kreitenberg, It’s, Berkowitz, Ziga, ” Kreitenberg, “ They’re, Melanie Radzicki McManus Organizations: CNN, Arthritis Foundation, Rheumatology Therapeutics Medical, “, CNN’s Locations: Tarzana , California, New York’s Westchester County
☆ Wall Street expects Trump presidency will unlock deal-making
  + stars: | 2024-11-07 | by ( Lillian Rizzo Gabrielle Fonrouge Rohan Goswami Annika Kim Constantino | Lillian Rizzo | Gabrielle Fonrouge | ) www.cnbc.com   time to read: +6 min
Trump defeated Democratic candidate Vice President Kamala Harris, and Republicans claimed a majority of the Senate in elections this week. "We know kind of where the world is headed in a Trump environment because we've seen it before," said Jeffrey Solomon, president of TD Cowen, on CNBC's "Money Movers" Wednesday. One M&A advisor, who also spoke to CNBC anonymously, noted that Trump's disdain for Big Tech companies — historically active deal-makers — might keep them on the sidelines. Apparent GOP opposition to the CHIPS Act means that semiconductor consolidation might be challenging, the advisor noted, while cautioning it is still too early to know what a Trump presidency would mean. That advisor noted that smaller banks had been getting gobbled up for "some time," but that the pace and size of those acquisitions would likely ramp up under a Trump presidency.
Persons: Donald Trum, Ronda Churchill, Donald Trump, Kamala Harris, Jeffrey Solomon, TD Cowen, Solomon, Trump, Lina Khan, Khan, Howard Gutman, Jonathan Miller, —, Jared Holz, Mizuho, Sen, Elizabeth Warren, David Zaslav, David Grogan Organizations: Republican, Nevada GOP, Afp, Getty, Trump, Democratic, Republicans, Biden administration's Department of Justice, Federal Trade Commission, CNBC, Dow Jones, MorganFranklin Consulting, Big Tech, Qualcomm, Intel, Integrated Media, Pharmaceutical, Biotech, Illumina, FTC, Maze Therapeutics, Sanofi, Senate, DOJ, Allen & Company Sun Valley Conference Locations: Florida, Nevada, Las Vegas , Nevada, Ronda, Trump, Sun Valley , Idaho
☆ Cathie Wood positions for new tech boom - and it doesn't matter who wins the White House
  + stars: | 2024-11-05 | by ( Stephanie Landsman | ) www.cnbc.com   time to read: +2 min
ARK Invest's Cathie Wood is positioning for a White House administration that embraces transformative technology. Wood runs the firm's flagship ARK Innovation ETF (ARKK) — which is up almost 22% over the past three months. After soaring nearly 68% last year, the ARK Innovation ETF is down about 8% in 2024. Wood is also behind the ARK Genomic Revolution ETF (ARKG) , which is down about 25% so far this year. The ARK Genomic Revolution ETF owns both stocks.
Persons: Wood, it's, Joe Biden, ARKK Organizations: White, Innovation, Federal Reserve, Tech, Genomic, Beam Therapeutics Locations: ARKK
☆ The trader guide to the election: Which stocks Wall Street expects to benefit under Trump or Harris
  + stars: | 2024-11-05 | by ( Fred Imbert | ) www.cnbc.com   time to read: +10 min
Generally, a Trump win is seen as positive for financials given a higher likelihood of deregulation for companies in the space. Traditional oil and gas names are also likely to benefit under a second Trump presidency. One is made up of stocks that benefit after a Harris win; the other would outperform under a second Trump presidency. However, a Harris win is expected to keep current regulation measures in place, and possibly introduce new ones. Private equity giants KKR and Blackstone would also benefit under a Trump win.
Persons: Kamala Harris, Donald Trump, Paul Gallant, Cowen, Gallant, Harris, Goldman Sachs, Daniel Clifton, Strategas, Andrew Garthwaite, Trump, Garthwaite, TAN, we've, Biden, Wells, Ike Boruchow, Boruchow, —, Russell, Joe Biden, Morgan Stanley, Crypto, isn't, Nic Puckrin, bitcoin, Marcelli, Financials, Wolfe, Chris Senyek, Lazard Organizations: Congress, U.S ., Trump, U.S . Trump, GOP, Democratic, CNBC Pro, Wall, Strategas, Enterprise, of America, Ford, UBS, Apple, Enphase Energy, Technologies Enphase, Exxon Mobil, Chevron, Trump Media & Technology, Trump Media, Cadence Bank, Viking Therapeutics, Bureau, CNBC, Wolfe Research, Lazard, Private, KKR, Blackstone, Evercore Locations: Washington, of America Cleveland, Cleveland, China
☆ Viking Therapeutics soars then drops on obesity data
  + stars: | 2024-11-04 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailViking Therapeutics soars then drops on obesity dataJared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector.
Persons: Jared Holz Organizations: Therapeutics, Viking Therapeutics Locations: Mizuho
☆ Cramer raves about Salesforce's star-powered plan to raise awareness of its new AI agents
  + stars: | 2024-11-04 | by ( Matthew J. Belvedere | ) www.cnbc.com   time to read: +3 min
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. In his Sunday column, meanwhile, Jim Cramer looked at 11 earnings surprises , including a feeling that both presidential candidates would support solar. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, There's, that's, there's, Eli Lilly, Lilly, Stanley Black, Decker, Nextracker, Jim, Salesforce, Evercore, Agentforce, he's, Saleforce's, Matthew McConaughey, Stocks, Sherwin, Berkshire Hathaway, Jim Cramer's, NVDA Organizations: CNBC, Fed, Devices, Nvidia, Intel, Dow, Therapeutics, Depot, ISI, Abercrombie, Fitch, Constellation Energy Locations: Friday's, Williams, Berkshire, Marriott
☆ Stocks making the biggest moves premarket: Trump Media, Talen, Nvidia, Apple and more
  + stars: | 2024-11-04 | by ( Sean Conlon | ) www.cnbc.com   time to read: +3 min
The drug is classified as a GLP-1, which could put the company in competition with Novo Nordisk and Eli Lilly. Berkshire Hathaway – Shares were marginally lower after Warren Buffett's conglomerate revealed that operating earnings totaled $10.1 billion in the third quarter . Berkshire Hathaway shares were marginally lower after operating earnings totaled $10.1 billion in the third quarter. Trump Media & Technology Group – Shares of former President Donald Trump's media company pulled back more than 3% ahead of the U.S. election on Tuesday. Shares of Intel were more than 1% lower, while Dow Inc. shares were off 0.6%.
Persons: Talen, Eli Lilly, Berkshire Hathaway, Warren Buffett's, Warren Buffett's Berkshire Hathaway, Peter Stern, Donald Trump's, Roblox, Morgan Stanley, Jefferies, Sherwin, Williams, William, CNBC's Hakyung Kim, Brian Evans, Sarah Min, Lisa Kailai Han, Spencer Kimball, Tanaya Macheel, Michelle Fox Theobald Organizations: Energy, Federal Energy Regulatory Commission, Susquehanna, Constellation, Therapeutics, Novo Nordisk, Apple, Berkshire, –, Bank of America, Trump Media & Technology, Nvidia, Dow Jones, Intel, Dow Inc
☆ At-home brain stimulation relieves symptoms of depression, study finds
  + stars: | 2024-11-01 | by ( Brenda Goodman | ) edition.cnn.com   time to read: +8 min
CNN —A headset worn at home that zaps the brain with the energy of a 9-volt battery could help relieve symptoms of depression, a new study shows. Rebalancing brain activity in depressionThe device is available in the UK, Norway, Hong Kong and countries in the EU. Studies show that people with depression tend to have less brain activity than normal in the dorsolateral prefrontal cortex and more brain activity than normal in the ventromedial prefrontal cortex. A ‘spicy’ sensation with brain benefitsLeana De Hoyos, a 34-year-old mother of two who lives in Houston, was one of the study participants. Helping people use brain stimulation at homeFu says that when her team started looking at transcranial direct current stimulation for depression, they first reviewed the medical literature.
Persons: ”, Rodrigo Machado, Vieira, Machado, It’s, it’s overactive, Daniel Mansson, Cynthia Fu, Fu, Leana De Hoyos, De Hoyos, didn’t, ” De Hoyos, I’m, you’ve, “, ’, ” Fu, Dr, Sanjay Gupta, “ We’re, Mansson, hasn’t Organizations: CNN, Nature Medicine, Therapeutics, US Food and Drug Administration, Neuroscience, King’s College London, CNN Health, “ Locations: UTHealth, Norway, Hong Kong, Swedish, United States, Houston, Europe
☆ 30 essential tips for living a longer, happier, more successful life with no regrets
  + stars: | 2024-10-31 | by ( Aditi Shrikant | ) www.cnbc.com   time to read: +6 min
The anti-aging market is littered with innovative products and procedures that promise consumers a healthier, happier, longer life. But prolonging your life isn't only about physical fitness: a near 90-year-long study from Harvard University found that those who live happier, longer lives have good relationships. If you want to live longer and feel more fulfilled you probably don't need lasers or freezers. 30 essential tips for living a longer, happier, more successful life1. If you can't drive, don't live somewhere where the doctor is a 30-minute car ride away.
Persons: superagers, dieticians, Warren, Buffets, Valter Longo, David Watson, Warren Buffet, Neil Paulvin, Danielle Miura, Mark La Spisa, García, Francesc Miralles, Charlie, Munger, Warren Buffett, it's, Thema Bryant Organizations: Harvard University, Italy —, Cancer Laboratory, IFOM, of Oncology, University of Notre Dame, GameStop Locations: New York City, Blue, Okinawa, Japan, Sardinia, Italy
☆ We're buying this stock for the second time this week, taking advantage post-earnings selling
  + stars: | 2024-10-31 | by ( Jeff Marks | ) www.cnbc.com   time to read: +3 min
Following Thursday's trade, Jim Cramer's Charitable Trust will own 525 shares of DHR, increasing its weighting to 3.67% from 3.5%. With expectations more reasonable, Danaher is in a better position to beat next year, which should lead to a higher stock price. Our Club price target on Danaher is $305 per share, a tad higher than Wolfe's, and it implies 26% upside to Wednesday's close. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.
Persons: Jim Cramer's, Danaher, Wolfe, Jim Cramer, Jim Organizations: DHR, Wolfe Research, CNBC Locations: Danaher
☆ Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales
  + stars: | 2024-10-29 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company's Covid vaccine and antiviral pill Paxlovid helped boost sales. Pfizer now expects revenue in a range of $61 billion to $64 billion, up from a previous revenue forecast of between $59.5 billion to $62.5 billion. That includes roughly $5 billion in expected revenue from its Covid vaccine and $5.5 billion from Paxlovid. Pfizer reported revenue of $17.7 billion for the third quarter, up 31% from the same period a year ago. Notably during the quarter, Pfizer withdrew from world markets a critical sickle cell drug it had acquired in a $5.4 billion deal for Global Blood Therapeutics.
Persons: Jeff Smith, Smith, Paxlovid, StreetAccount, Covid Organizations: Pfizer, LSEG, Global Blood Therapeutics Locations: U.S
☆ This biotech stock is breaking out after an 8-month standoff between the bulls and bears
  + stars: | 2024-10-25 | by ( Carter Braxton Worth | ) www.cnbc.com   time to read: +2 min
Viking Therapeutics (VKTX) ... the eight-month standoff is at an end. After surging to $100 in mid February, Viking Therapeutics, has slumped some 40% in the ensuing eight months, and just now is coming to life. Two identical charts below: Converging trendlines... otherwise known as a symmetrical triangle chart pattern, depict the standoff of the past 8 months. A well-defined series of lower highs and lower lows, as the stock works into the apex of the formation. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.
Persons: Carter Worth, Carter Braxton Worth Organizations: Viking Therapeutics, CNBC, NBC UNIVERSAL
☆ Here are the 5 things that could move the stock market in the week ahead
  + stars: | 2024-10-20 | by ( Zev Fima | ) www.cnbc.com   time to read: +10 min
Earnings drove the stock market higher — can they do it again in the week ahead? But he acknowledged that timing is key because our portfolio discipline mandates that we consider lightening up our stock exposure in an overbought market. In fact, AMD was our worst-performing stock for the entire week, losing more than 7% following the prior week's 1.8% slide. Energy was the worst sector of the week for the market as oil prices sank. In the week ahead, housing numbers are the main draw on the economic front.
Persons: Jim Cramer, ASML, Morgan Stanley, WTI, industrials, We're, Sartorius, Danaher, we're, Stanley Black, Lockheed Martin, Philip Morris, Clark, Baker Hughes, Lam, DOV, CARR, Davidson, Northrop, Edwards Lifesciences, Jim Cramer's, Jim, Stocks, Tuesday's, Spencer Platt Organizations: Dow, Nasdaq, Netflix, Modelo, Corona, Constellation Brands, Taiwan Semiconductor Manufacturing Company, Nvidia, AMD, Broadcom, Club, Abbott Laboratories, Energy, Texas, Honeywell, Danaher, Federal Reserve, Treasury, SAP, Logitech, Verizon, General Motors, GE Aerospace, GE, Lockheed, Quest Diagnostics, Norfolk Southern, Polaris, Seagate Technology, Texas Instruments, Canadian National Railway Company, Boeing, GE Vernova, Fisher, Boston, General Dynamics, Hilton, Lam Research, Business Machines, IBM, Newmont, Viking Therapeutics, Vista Energy, Mattel, O'Reilly Automotive, Whirlpool, American Airlines, United Parcel Service, Southwest Airlines, Tractor Supply Company, Carrier Global, Dow Chemical, DOW, Harley, Union Pacific, Valero Energy, Hasbro, Northrop Grumman, Ryder, Boyd Gaming, Western, Boston Beer Company, York Community Bancorp, Colgate, Palmolive, Newell Brands, Jim Cramer's Charitable, CNBC, NEW, Traders, New York Stock Exchange, Getty Locations: BlackRock, CrowdStrike, U.S, Dover, Freeport, McMoRan, Kimberly, Norfolk, Las, ORLY, VALE, New York City
☆ These 9 biotech stocks have doubled this year and are set to double again, analysts say
  + stars: | 2024-10-17 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +4 min
Nine health-care stocks have more than doubled in price this year, but still have more than 100% upside potential, according to analysts. All have a "buy" or equivalent rating, and every single one expects the stock to more than double over the next 12 months. The median average price target of $66.50 from eight analysts points to a 252% upside potential over the next 12 months. Benitec is expected to rise by 104% over the next 12 months, according to the median price target of five analysts. Humacyte has doubled this year, and analysts expect it to double again over the next 12 months.
Persons: Benitec, Arcutis, Stocks, Rezolute Rezolute, Trevi, Arcutis Biotherapeutics, Humacyte Organizations: CNBC Pro, Nasdaq, Jasper Therapeutics, Corbus Pharmaceuticals, Rezolute, Trevi Therapeutics, Delcath Systems, Precision Medicines, Jasper Therapeutics Jasper Therapeutics, Pharmaceuticals Corbus Pharmaceuticals, Trevi Therapeutics Trevi Therapeutics, Systems Delcath Systems, Praxis, Medicines Locations: Jasper, Jasper Therapeutics Jasper, Massachusetts, California, U.S, Europe, Australia, Hayward , California
☆ Ark Invest's flagship fund realized $3.5 billion in losses in a year. Here were its 10 biggest losers.
  + stars: | 2024-10-16 | by ( Matthew Fox | ) www.businessinsider.com   time to read: +3 min
Ark Invest's Innovation ETF realized $3.5 billion in losses in the fiscal year ending July 2024. AdvertisementCathie Wood's Ark Invest recently filed its annual report for its fiscal year ending July 31, and it reveals some steep losses. Ark's flagship Innovation ETF realized $3.5 billion in losses from July 31, 2023, through July 31, 2024. The Ark Innovation ETF is down 9% year-to-date and off 70% from its record high. AdvertisementHere are the stocks in Ark Invest's flagship ETF that saw the biggest realized losses for the fiscal year ending July 31.
Persons: Cathie Wood, —, Wood, Ark's Organizations: Ark Invest, Service, Invest, Times, Veracyte, Beam Therapeutics, Teladoc
0 next >>
Total: 25